Drug profile · INN
imiquimod
ALDARA
imiquimod (ALDARA) is a toll-like receptor 7 agonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: topical. Current US regulatory status: approved.
Drug details — imiquimod
- US status
- approved
- Class
- Dermatologicals (D06)
- Route
- TOPICAL
- Patents
- 0
- Programs
- 9
- Data quality
- 0.89
Quick answer
imiquimod (ALDARA) is a toll-like receptor 7 agonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
Toll-like receptor 7 agonist
Primary target: Toll-like receptor 7
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is imiquimod?
imiquimod (ALDARA) is a toll-like receptor 7 agonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for imiquimod?
ALDARA is a marketed brand name for imiquimod. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of imiquimod?
imiquimod has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.